Louisville-based GlobeImmune Inc. has reduced the size of its proposed initial public offering by $10 million, according to a filing made Wednesday with the U.S. Securities and Exchange Commission. GlobeImmune, a biopharmaceutical firm developing drugs to treat cancers and infectious diseases, now plans to offer 1,562,500 shares, down from 2,187,500 shares. The pricing remained in the $15 to $17 range.
Help employers find you! Check out all the jobs and post your resume.
